MPN Treatment

What Does the Discussion Around Changing MF Treatments Look Like?

Myelofibrosis (MF) patients have more options than ever. In the first installment of this series, MF patient and Patient Power co-founder Andrew Schorr talks to John Mascarenhas, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, about switching treatments. In the age of personalized medicine, what should the dialogue around making a change to one’s treatment cover? Andrew and Dr. Mascarenhas guide patients through many facets of decision making around what to expect during a transition, dosing, and more.

Sponsored Content

Information produced by Patient Power in collaboration with CTI Biopharma.

© 2024 HealthCentral LLC. All rights reserved.